“End2End announces the launch of Halozyme Therapeutics's New Web Site”

September 12, 2007

Halozyme TherapeuticsSAN DIEGO, September 12, 2007 – End2End Integration is pleased to announce the launch of Halozyme Therapeutics new Web Site (www.halozyme.com).

In 2007, Halozyme Therapeutics engaged End2End to re-envision their online identity and design their new web site. With a focus on usability, the new site provides visitors with a seamless user experience, while simultaneously communicating Halozyme's brand identity.

About Halozyme Therapeutics

Halozyme is a biopharmaceutical company developing and commercializing products based on the extracellular matrix (matrix) for the drug delivery, oncology, and dermatology markets. The company's portfolio of products is based on intellectual property covering the family of human enzymes known as hyaluronidases. Our three primary programs are to Enable, Improve and Innovate, leveraging our unique expertise in the matrix. Specifically, our Enable program focuses on HYLENEX and our Enhanze™ Technology for drug delivery. Our Improve program focuses on extending potential patient benefits through the co-formulation of rHuPH20 with marketed small molecules, particularly oncology and bisphosphonate drugs. And, finally, our Innovate program focuses on developing and commercializing new molecular entities targeting the extracellular matrix with emphasis on oncology and dermatology.

About End2End Integration

End2End is a strategic design and consulting organization that develops effective websites, powerful web applications, and successful branding solutions. Since 2001, End2End has employed a multi-disciplinary strategic culture that unites the most effective elements of research, design, and technology. End2End’s user-centric methodology empowers business process, promotes competitive advantage, and maximizes returns on internet based initiatives. For more information, please visit www.e2ei.com